Edgewise Therapeutics, Inc. EWTX
We take great care to ensure that the data presented and summarized in this overview for Edgewise Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding EWTX
View all-
Orbimed Advisors LLC San Diego, CA15MShares$248 Million10.86% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.91MShares$147 Million3.85% of portfolio
-
Baker Bros. Advisors LP New York, NY6.16MShares$102 Million1.82% of portfolio
-
Black Rock Inc. New York, NY6.02MShares$99.5 Million0.0% of portfolio
-
Novo Holdings Hellerup, G75MShares$82.7 Million10.85% of portfolio
-
Janus Henderson Group PLC London, X04.98MShares$82.4 Million0.07% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.49MShares$74.3 Million4.58% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.47MShares$73.9 Million0.0% of portfolio
-
Cormorant Asset Management, LP Boston, MA3.41MShares$56.3 Million7.18% of portfolio
-
Perceptive Advisors LLC New York, NY2.69MShares$44.4 Million2.39% of portfolio
Latest Institutional Activity in EWTX
Top Purchases
Top Sells
About EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Insider Transactions at EWTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 02
2025
|
Joanne M. Donovan CMO |
SELL
Open market or private sale
|
Direct |
5,187
-19.37%
|
$82,992
$16.45 P/Share
|
|
May 02
2025
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
4,276
-17.18%
|
$68,416
$16.45 P/Share
|
|
May 02
2025
|
John R Moore General Counsel |
SELL
Open market or private sale
|
Direct |
1,930
-22.81%
|
$30,880
$16.45 P/Share
|
|
May 02
2025
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,551
-7.73%
|
$24,816
$16.45 P/Share
|
|
May 02
2025
|
R Michael Carruthers Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,314
-1.6%
|
$21,024
$16.45 P/Share
|
|
May 02
2025
|
Behrad Derakhshan Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,691
-7.67%
|
$27,056
$16.45 P/Share
|
|
May 01
2025
|
Joanne M. Donovan CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,417
+28.01%
|
-
|
|
May 01
2025
|
Kevin Koch President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,417
+29.5%
|
-
|
|
May 01
2025
|
John R Moore General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,209
+38.11%
|
-
|
|
May 01
2025
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,209
+20.6%
|
-
|
|
May 01
2025
|
R Michael Carruthers Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,209
+5.95%
|
-
|
|
May 01
2025
|
Behrad Derakhshan Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,209
+19.11%
|
-
|
|
Apr 03
2025
|
Peter A. Thompson Director |
BUY
Open market or private purchase
|
Indirect |
496,771
+12.16%
|
$9,935,420
$20.13 P/Share
|
|
Apr 03
2025
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
496,771
+12.16%
|
$9,935,420
$20.13 P/Share
|
|
Apr 01
2025
|
Jonathan C Fox |
BUY
Grant, award, or other acquisition
|
Direct |
559
+4.67%
|
-
|
|
Mar 07
2025
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
100
-0.69%
|
$3,000
$30.0 P/Share
|
|
Mar 07
2025
|
Kevin Koch President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.68%
|
$0
$0.18 P/Share
|
|
Mar 07
2025
|
Alan J Russell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
200
-1.33%
|
$6,000
$30.02 P/Share
|
|
Mar 07
2025
|
Alan J Russell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+1.31%
|
$0
$0.18 P/Share
|
|
Feb 06
2025
|
Kevin Koch President and CEO |
SELL
Open market or private sale
|
Direct |
900
-5.85%
|
$27,900
$31.13 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 994K shares |
|---|---|
| Exercise of conversion of derivative security | 579K shares |
| Grant, award, or other acquisition | 559 shares |
| Open market or private sale | 520K shares |
|---|